CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 109 enrolled
Drug / intervention
MP-424 +2 moredrug
Likely dose
MP-424 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00780910
NCT00780910Phase 3Completed
CompareCT.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment

Tanabe Pharma Corporation·interventional·Posted Oct 28, 2008·Updated Jan 6, 2026

In Brief

A Phase 3 clinical trial evaluating MP-424, Ribavirin, and 1 other intervention for Chronic Hepatitis C. Completed, enrolled 109 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesJapan
CollaboratorsVertex Pharmaceuticals Incorporated

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 28, 2008
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.7 years ago

Interventions

MP-424drug

750 mg every 8 hours for 12 weeks

Ribavirindrug

600 - 1000 mg/day based on body weight for 24 weeks

Peginterferon Alfa-2bdrug

1.5 mcg/kg/week for 24 weeks